62 Participants NeededMy employer runs this trial

PSMA PET Scans for Prostate Cancer

AS
Overseen ByAbhinav Sidana, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether adding PSMA PET scans (a type of imaging test) to routine MRI scans can better detect prostate cancer recurrence in men. It focuses on those who have already undergone focal therapy, which targets only part of the prostate. Men diagnosed with non-metastatic prostate cancer and scheduled for more focused treatment might be suitable candidates. The aim is to determine if these combined imaging tests provide clearer results for early cancer detection. As an unphased trial, this study offers a unique opportunity to advance imaging techniques for improved cancer detection.

What prior data suggests that PSMA PET scans are safe for detecting prostate cancer recurrence?

Research has shown that PSMA PET scans are generally safe for detecting prostate cancer. These scans use a special dye to highlight cancer cells. Studies have found that the radiation from these scans is safe. However, about 15% of patients may experience some pain at the scan site. The FDA has approved PSMA PET scans for certain prostate cancer cases, indicating a strong safety record. While some temporary side effects may occur, the benefits typically outweigh the risks.12345

Why are researchers excited about this trial?

Researchers are excited about PSMA PET/CT scans for prostate cancer because they offer a highly specific imaging technique that can detect cancer cells more accurately than traditional methods. Unlike conventional imaging like bone scans and CT scans, PSMA PET/CT uses a special tracer that binds to the Prostate-Specific Membrane Antigen (PSMA) on prostate cancer cells, making even small or hidden tumors visible. This means it can potentially improve diagnosis, help in staging the cancer more precisely, and guide better treatment decisions, which can lead to more personalized and effective care for patients.

What evidence suggests that PSMA PET scans are effective for detecting prostate cancer recurrence?

Studies have shown that PSMA PET/CT scans effectively detect prostate cancer. These scans are significantly more accurate than regular imaging, improving detection by about 27%. Research indicates that these scans assist doctors in selecting the best treatment for patients with recurrent prostate cancer. PSMA PET/CT scans also correlate with better survival rates, with about three-quarters of patients avoiding cancer spread to distant areas after five years. This scan uses a special dye that adheres to prostate cancer cells, making it easier to visualize cancer throughout the body. All participants in this trial will undergo the PSMA PET/CT scan as part of the study interventions.678910

Who Is on the Research Team?

AS

Abhinav Sidana, MD

Principal Investigator

University of Chicago

Are You a Good Fit for This Trial?

Inclusion Criteria

I am a man and at least 18 years old.
I can understand and have signed the consent form.
I can take care of myself but might not be able to do heavy physical work.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Follow-up

Participants receive PSMA PET and mpMRI scans to monitor for prostate cancer recurrence after focal therapy

12 months
Regular visits for imaging and sample collection

Long-term follow-up

Participants are monitored for long-term outcomes and effectiveness of imaging techniques

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • PSMA PET/CT scan

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: All participantsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials
1,086
Recruited
844,000+

Blue Earth Diagnositcs

Collaborator

Citations

Long-Term Outcomes of Prostate-Specific Membrane Antigen ...

The findings suggest that assuming modest benefits of earlier detection, PSMA-PET imaging could improve the length and quality of life for ...

The Use of PSMA PET/CT Improves Overall Survival in Men ...

Comparatively, the 3-y BRFS rate was consistent with overall survival: 74.9% (95% CI, 68.5%–81.3%) for PSMA PET/CT patients and 69.4% (95% CI, ...

How can PSMA PET/CT scans help guide recurrent ...

The 5-year outcomes underscore the impact of PSMA PET/CT-guided sRT. At 5 years, approximately three-quarters of patients were free from distant ...

The Evolving Role of PSMA-PET/CT in Prostate Cancer ... - PMC

A post-therapy decline in PSMA-positive tumor volume ≥ 30% correlates with improved overall survival in metastatic castration-resistant prostate ...

Usefulness and Limitations of PSMA Imaging/PET in High- ...

Following first-line PSMA PET/CT, 20 (14%) of 148 patients were directed from curative to palliative-intent treatment, 11 (7%) had a change in ...

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

PSMA PET-CT has improved the detection of loco-regional and metastatic disease. PSMA PET-CT also has a role in the primary diagnosis and staging.

PSMA PET scan for prostate cancer

The amount of radiation is considered safe. Your healthcare team carefully weighs the risks of radiation from the combined PET-CT scan against ...

PSMA-PET/CT Findings in Patients With High-Risk ...

Patients' cancers were understaged by conventional imaging; PSMA-PET results were positive in 84% of patients, PSMA-PET detected M1 disease ...

Side Effects of PSMA PET Scan: 7 Key Facts

A study in the Journal of Nuclear Medicine found that about 15% of patients reported localized pain after PET scans. While specific data for PSMA PET scans ...

The Current Landscape of PSMA PET Imaging in Prostate ...

PSMA PET/CT is currently FDA approved for the initial staging of patients with presumed localized, high-risk prostate cancer and for the diagnostic work up of ...